Brief: Cabaletta Bio - Cash, Cash Equivalents And Short-Term Investments Expected To Support Operations Into Q4 2025
09/11/2023 12:34
Nov 9 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
AND
PROVIDES BUSINESS UPDATE
* CABALETTA BIO INC - CASH, CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS EXPECTED TO SUPPORT OPERATIONS INTO Q4 OF 2025
Source text for Eikon: ID:nGNX6NZsS3
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity